<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02345915</url>
  </required_header>
  <id_info>
    <org_study_id>LEA-JA-IPC 2014-005</org_study_id>
    <nct_id>NCT02345915</nct_id>
  </id_info>
  <brief_title>Evaluation of Adverse Long-term Effects in Young Adult Survivors of Acute Leukemia</brief_title>
  <acronym>LEA-JA</acronym>
  <official_title>Evaluation of Adverse Long-term Effects in Young Adult Survivors of Acute Leukemia-LEA-JA-IPC 2014-005</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Paoli-Calmettes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aix Marseille Université</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut Paoli-Calmettes</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Taking into account the specificities of adolescent and young adult cancer patients led&#xD;
      agencies (in particular the French National Cancer Institute INCa, through the last Cancer&#xD;
      Plan), to initiate projects targeting this population. Acute leukemia is among the most&#xD;
      common cancers in adolescents and young adults. Recent therapeutic advances now allow hope&#xD;
      for a cure in about 50% of this population. The issue of post-cancer is therefore of&#xD;
      particular importance for young adults with cancer. Our aim is to establish the health&#xD;
      determinants in young adult leukemia survivors and to compare the frequency of these effects&#xD;
      and their explanatory factors to the data collected in children or adolescent leukemia&#xD;
      survivors program (LEA). 90 patients followed up at the Institut Paoli-Calmettes cancer&#xD;
      center and Nice University Hospital have been identified and would be included in this&#xD;
      study.Collected data will include information on the initial disease and its treatments,&#xD;
      physical sequelae (fertility, thyroid function, heart function, visual function, secondary&#xD;
      tumors, viral infections, lung function, bone metabolism, iron metabolism, metabolic&#xD;
      syndrome, osteonecrosis, alopecia ... ), quality of life, social and occupational integration&#xD;
      and relationship with care system.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">November 2014</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Late sequelae evaluation of young adult acute leukemia-survivors</measure>
    <time_frame>24 mois</time_frame>
    <description>Main measured sequelae on: heart function, thyroid function, visual function, lung function, bone metabolism, secondary tumors, viral infections, iron metabolism, metabolic syndrome, gonadic, fertility, renal function, liver function,…</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality-of-life assessment of young adult acute leukemia-survivors</measure>
    <time_frame>24 mois</time_frame>
    <description>Quality of life questionnaire</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of the frequency of sequelae between children/adolescents (LEA cohort) and young adults acute leukemia survivors (LEA-JA)</measure>
    <time_frame>24 mois</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Leukemia, Myeloid, Acute</condition>
  <condition>Acute Lymphoid Leukemia</condition>
  <arm_group>
    <arm_group_label>Young adult acute leukemia-survivor</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood sample</intervention_name>
    <arm_group_label>Young adult acute leukemia-survivor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Electrocardiogram</intervention_name>
    <arm_group_label>Young adult acute leukemia-survivor</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Young adult (18-40 years) Leukemia survivor, in complete remission.&#xD;
&#xD;
          -  Acute leukemia diagnosed since January 1980 .&#xD;
&#xD;
          -  Patient Affiliated to social security or beneficiary&#xD;
&#xD;
          -  Signed Informed Consent prior to any screening procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Emergency&#xD;
&#xD;
          -  Patient unable to abide by the study protocol (for geographical, social or&#xD;
             psychological reasons)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Norbert VEY, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Paoli-Calmettes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dominique GENRE, MD</last_name>
    <phone>0033491223778</phone>
    <email>drci.up@ipc.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jihane Pakradouni, PharmD PhD</last_name>
    <phone>0033491223778</phone>
    <email>drci.up@ipc.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut Paoli-Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13009</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominique Genre, MD</last_name>
      <phone>0033491223778</phone>
      <email>drci.up@ipc.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Norbert VEY, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <study_first_submitted>December 5, 2014</study_first_submitted>
  <study_first_submitted_qc>January 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2015</study_first_posted>
  <last_update_submitted>September 1, 2017</last_update_submitted>
  <last_update_submitted_qc>September 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

